JP2020500882A - トレプロスチニルおよびその塩の皮膚投与および経皮投与方法 - Google Patents

トレプロスチニルおよびその塩の皮膚投与および経皮投与方法 Download PDF

Info

Publication number
JP2020500882A
JP2020500882A JP2019529890A JP2019529890A JP2020500882A JP 2020500882 A JP2020500882 A JP 2020500882A JP 2019529890 A JP2019529890 A JP 2019529890A JP 2019529890 A JP2019529890 A JP 2019529890A JP 2020500882 A JP2020500882 A JP 2020500882A
Authority
JP
Japan
Prior art keywords
treprostinil
tds
drug
skin
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019529890A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500882A5 (enExample
Inventor
シャオミン チャン
シャオミン チャン
サイラス ケイ． ベッカー
サイラス ケイ． ベッカー
ミーナクシ エス． ヴェンカトラマン
ミーナクシ エス． ヴェンカトラマン
Original Assignee
コルセア ファーマ インコーポレイテッド
コルセア ファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コルセア ファーマ インコーポレイテッド, コルセア ファーマ インコーポレイテッド filed Critical コルセア ファーマ インコーポレイテッド
Publication of JP2020500882A publication Critical patent/JP2020500882A/ja
Publication of JP2020500882A5 publication Critical patent/JP2020500882A5/ja
Priority to JP2023114183A priority Critical patent/JP2023134620A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019529890A 2016-12-05 2017-12-05 トレプロスチニルおよびその塩の皮膚投与および経皮投与方法 Pending JP2020500882A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023114183A JP2023134620A (ja) 2016-12-05 2023-07-12 トレプロスチニルおよびその塩の皮膚投与および経皮投与方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662430053P 2016-12-05 2016-12-05
US62/430,053 2016-12-05
PCT/US2017/064612 WO2018106632A1 (en) 2016-12-05 2017-12-05 Dermal and transdermal administration of treprostinil and salts thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023114183A Division JP2023134620A (ja) 2016-12-05 2023-07-12 トレプロスチニルおよびその塩の皮膚投与および経皮投与方法

Publications (2)

Publication Number Publication Date
JP2020500882A true JP2020500882A (ja) 2020-01-16
JP2020500882A5 JP2020500882A5 (enExample) 2021-01-07

Family

ID=60782377

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019529890A Pending JP2020500882A (ja) 2016-12-05 2017-12-05 トレプロスチニルおよびその塩の皮膚投与および経皮投与方法
JP2023114183A Pending JP2023134620A (ja) 2016-12-05 2023-07-12 トレプロスチニルおよびその塩の皮膚投与および経皮投与方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023114183A Pending JP2023134620A (ja) 2016-12-05 2023-07-12 トレプロスチニルおよびその塩の皮膚投与および経皮投与方法

Country Status (8)

Country Link
US (1) US20190290597A1 (enExample)
EP (1) EP3548010A1 (enExample)
JP (2) JP2020500882A (enExample)
KR (2) KR20230119035A (enExample)
CN (1) CN110381930A (enExample)
CA (1) CA3045917A1 (enExample)
IL (1) IL267046A (enExample)
WO (1) WO2018106632A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022196748A1 (ja) * 2021-03-17 2022-09-22 国立大学法人九州大学 経皮吸収剤
WO2023085282A1 (ja) * 2021-11-15 2023-05-19 東洋インキＳｃホールディングス株式会社 セレキシパグを有効成分とする貼付剤
JP2025515512A (ja) * 2022-04-29 2025-05-15 兆科薬業（広州）有限公司 トレプロスチニルソフトミスト吸入剤

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6542128B2 (ja) 2013-01-11 2019-07-10 コルセア ファーマ インコーポレイテッド トレプロスチニルのプロドラッグ
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11607026B2 (en) * 2014-05-30 2023-03-21 Johnson & Johnson Consumer Inc. Device for delivery of skin care composition
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
WO2019218006A1 (en) * 2018-05-14 2019-11-21 Butterworth Building Oil therapy method and device
AU2019344541B2 (en) * 2018-09-18 2022-01-06 Eli Lilly And Company Erbumine salt of treprostinil
US20230293352A1 (en) * 2020-08-16 2023-09-21 Ofer Spottheim Medical dressing
EP4313007A4 (en) * 2021-03-31 2025-03-12 Lyfe CHNG, LLC TRANSDERMAL SYSTEM, FORMULATION AND METHOD FOR THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT
CN113842377A (zh) * 2021-08-11 2021-12-28 杭州师范大学 一种经皮递送榄香烯的pdms微针贴片及其制备方法
WO2023114755A1 (en) * 2021-12-13 2023-06-22 WELSH Stephen Adhesive bandage system for medication delivery and indication of procedure location
WO2023144276A1 (en) * 2022-01-27 2023-08-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of selexipag
WO2024015602A1 (en) * 2022-07-15 2024-01-18 Aso Llc Therapeutic foot patch for cough treatment
CN118178292B (zh) * 2024-03-07 2024-10-01 广州博科化妆品有限公司 一种含有水蛭素和植物提取物的防脱洗发露及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0687749A (ja) * 1990-05-24 1994-03-29 Wellcome Found Ltd:The 医薬用プロスタグランジン類縁体
KR20110042028A (ko) * 2008-03-31 2011-04-22 알테아 쎄라퓨텍스 코포레이션 침투제 전달 시스템 및 그의 사용방법
US9394227B1 (en) * 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4262003A (en) 1975-12-08 1981-04-14 Alza Corporation Method and therapeutic system for administering scopolamine transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US5234690A (en) 1991-08-23 1993-08-10 Cygnus Therapeutic Systems Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
CA2959852A1 (en) 2003-05-22 2005-01-27 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs
WO2005009510A2 (en) 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
CN101647792B (zh) * 2003-12-16 2012-11-28 联合治疗公司 曲前列环素在制备治疗和预防缺血性损害的药物中的用途
DE602005020269D1 (de) * 2004-04-12 2010-05-12 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
US8350079B2 (en) 2008-05-08 2013-01-08 United Therapeutics Corporation Treprostinil formulation
US20110294815A1 (en) 2008-06-27 2011-12-01 Harbeson Scott L Prostacyclin analogs
US9327105B2 (en) * 2010-03-26 2016-05-03 Itrace Biomedical Inc. Active transdermal drug delivery system and the method thereof
CN103193627B (zh) 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
CN103193626B (zh) 2012-01-10 2016-05-11 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
WO2014022376A2 (en) * 2012-08-01 2014-02-06 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
US9505737B2 (en) * 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
JP2016517410A (ja) 2013-03-14 2016-06-16 ユナイテッド セラピューティクス コーポレイション トレプロスチニルの固体形態

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0687749A (ja) * 1990-05-24 1994-03-29 Wellcome Found Ltd:The 医薬用プロスタグランジン類縁体
KR20110042028A (ko) * 2008-03-31 2011-04-22 알테아 쎄라퓨텍스 코포레이션 침투제 전달 시스템 및 그의 사용방법
US9394227B1 (en) * 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLAISE, S. ET AL: "Cathodal Iontophoresis of Treprostinil Induces a Sustained Increase in Cutaneous Blood Flux in Healt", PHARMACODYNAMICS, vol. 53, no. 1, JPN6023009423, 2013, pages 58 - 66, ISSN: 0005010630 *
CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 95, no. 4, JPN6021032633, 2014, pages 439 - 445, ISSN: 0005010629 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022196748A1 (ja) * 2021-03-17 2022-09-22 国立大学法人九州大学 経皮吸収剤
WO2023085282A1 (ja) * 2021-11-15 2023-05-19 東洋インキＳｃホールディングス株式会社 セレキシパグを有効成分とする貼付剤
JP2025515512A (ja) * 2022-04-29 2025-05-15 兆科薬業（広州）有限公司 トレプロスチニルソフトミスト吸入剤

Also Published As

Publication number Publication date
CA3045917A1 (en) 2018-06-14
KR20190109399A (ko) 2019-09-25
IL267046A (en) 2019-07-31
CN110381930A (zh) 2019-10-25
EP3548010A1 (en) 2019-10-09
JP2023134620A (ja) 2023-09-27
US20190290597A1 (en) 2019-09-26
KR20230119035A (ko) 2023-08-14
WO2018106632A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
JP2023134620A (ja) トレプロスチニルおよびその塩の皮膚投与および経皮投与方法
Akhtar et al. Non-invasive drug delivery technology: Development and current status of transdermal drug delivery devices, techniques and biomedical applications
Benson et al. Topical and transdermal drug delivery: principles and practice
US5750141A (en) Administration of vaso-active agent and therapeutic agent
JP5850889B2 (ja) 薬物の皮膚送達のための接着性外皮形成製剤とそれを使用する方法
ES2452517T3 (es) Composiciones y métodos para el tratamiento del trastorno de déficit de atención y del trastorno de déficit de atención e hiperactividad con metilfenidato
ES2388355T3 (es) Sistemas de suministro transdémico que comprenden bupivacaína
US20070280972A1 (en) Adhesive solid gel-forming formulations for dermal drug delivery
Tadicherla et al. Percutaneous dermal drug delivery for local pain control
JP5563473B2 (ja) マイクロニードル孔バイアビリティを向上させるための方法及び組成物
Williams Topical and transdermal drug delivery
CN102085198A (zh) 透皮给药系统
Ghaferi et al. Transdermal Drug Delivery Systems (TDDS): recent advances and failure modes
Deulkar et al. A review on transdermal drug delivery system
JP2020505322A (ja) 局所用デトミジン製剤
US20250205173A1 (en) Dermal and transdermal administration of treprostinil and salts thereof
Deshwal et al. Optimization techniques in transdermal drug delivery system
JP2007001938A (ja) 微細針付き貼付剤
HK40016649A (en) Dermal and transdermal administration of treprostinil and salts thereof
WO2015061910A1 (en) Topical formulations, systems, and methods
CN115666537B (zh) 缓释医用硬膏剂
Pinnamraju et al. A Review on Current Advances in Transdermal Drug Delivery Systems
Puri Enhanced delivery of actives through skin from patches and formulations, and distribution within and across skin
KR20060052931A (ko) 경피용 와파린-포함 전달 시스템
Jain Formulation Development, Optimization and Characterization of Lidocaine Topical Patch

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201117

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210823

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220901

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230822